5-year relative survival for Providence patients is higher than national survival as tracked by the Surveillance, Epidemiology, and End Results (SEER) Program. The survival statistics in the graph below indicate that survival is highest when lung cancer is caught at its earliest stages. The survival rate of patients with any stage of lung cancer treated at Providence exceeds average survival rates nationally.
5-year Relative Survival Rate: Lung Cancer
*See footnote for information on the above survival statistics and methods.
* The Providence patient groups include all patients diagnosed with cancer from 2009- 2015 who received all or part of their initial course of treatment at Providence Cancer Institute. The 5-year survival was calculated using Actuarial Survival methods. SEER relative-survival rates used for comparison are also for patients diagnosed from 2009-2015. These statistics are based on the November 2018 submission of data from the population-based SEER 18 registries and SEER*Stat Database. The survival rates have not been adjusted for age, gender, race/ethnicity or insurance status.
More information on SEER survival statistics and methods ›
National Standards of Cancer Care
Patients treated according to national guidelines for cancer care have the best survival rates and quality of life. Providence Cancer Institute meets or exceeds the targets set by the Commission on Cancer (CoC).
Commission on Cancer (CoC) Cancer Program Profile Reports (CP3R) Lung Performance Measures
||PPMC 2017 Performance1
||PSVMC 2017 Performance1
Systemic chemotherapy is administered within four months to day preoperatively or day-of-surgery to six months postoperatively, or it is recommended for surgically resected cases with pathologic lymph node positive (pN1) and (pN2) NSCLC (Quality Improvement)
|Surgery is not the first course of treatment for cN2, M0 lung cases (Quality Improvement)
1Most recent data available from our cancer registry
Learn more ›
* No CoC benchmark established at this time